ReviewMolecular cancer2022
Liquid biopsies to occult brain metastasis.
Review in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- Combining Napsin A expression with circulating tumor cell counts for enhanced identification of pulmonary adenocarcinoma in ground-glass nodules.Translational cancer research · 2026Article
- Downregulated lysyl oxidase in plasma extracellular vesicles: a biomarker linked to brain metastasis risk in lung adenocarcinoma.BMC medicine · 2026Article
- Single-cell advances in the investigation of the pathogenesis and treatment of brain metastasis.Neuro-oncology advances · 2026Review
- Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances.Military Medical Research · 2026Review
- Circulating MicroRNAs do not provide a diagnostic benefit over tissue biopsy in patients with brain metastases.Scientific reports · 2025Article
- Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.The journal of liquid biopsy · 2025Review
- Biomarkers of immunotherapy response in neuro-oncology.Neuro-oncology advances · 2025Review
- SPANXB1 drives brain metastasis in breast cancer via MMP1 regulation: potential therapeutic insights with metformin.Cell death discovery · 2025Article
- Cyst fluid ctDNA as a biomarker for genetic profiling and treatment monitoring in cystic brain metastases.British journal of cancer · 2025Article
- Cerebrospinal Fluid-Derived Genomic Alterations Tracking Glioma.Journal of molecular neuroscience : MN · 2025Article
- Hotspots and frontiers of extracellular vesicles and lung cancer: a bibliometric and visualization analysis from 2002 to 2024.Discover oncology · 2025Article
- Tumor Marker Test in Cerebrospinal Fluid for Leptomeningeal Metastasis Diagnosis and Response Assessment in Non-Small-Cell Lung Cancer.European journal of neurology · 2025Article
- Viable Cryopreservation Strategy for Extending the Timeframe of Circulating Tumor Cell Detection in Breast Cancer Clinical Trials.Biomolecules · 2025Article
- Refining Lung Cancer Brain Metastasis Models for Spatiotemporal Dynamic Research and Personalized Therapy.Cancers · 2025Review
- Liquid biopsies for the monitoring of gliomas and brain metastases in adults.Acta neuropathologica · 2025Review
- Article
- Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Molecular evolution of central nervous system metastasis and therapeutic implications.Trends in molecular medicine · 2025Review
- Progress in personalized immunotherapy for patients with brain metastasis.NPJ precision oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Brain metastasis (BrM) is a major problem associated with cancer-related mortality, and currently, no specific biomarkers are available in clinical settings for early detection. Liquid biopsy is widely accepted as a non-invasive method for diagnosing cancer and other diseases. We have reviewed the evidence that shows how the molecular alterations are involved in BrM, majorly from breast cancer (BC), lung cancer (LC), and melanoma, with an inception in how they can be employed for biomarker development. We discussed genetic and epigenetic changes that influence cancer cells to breach the blood-brain barrier (BBB) and help to establish metastatic lesions in the uniquely distinct brain microenvironment. Keeping abreast with the recent breakthroughs in the context of various biomolecules detections and identifications, the circulating tumor cells (CTC), cell-free nucleotides, non-coding RNAs, secretory proteins, and metabolites can be pursued in human body fluids such as blood, serum, cerebrospinal fluid (CSF), and urine to obtain potential candidates for biomarker development. The liquid biopsy-based biomarkers can overlay with current imaging techniques to amplify the signal viable for improving the early detection and treatments of occult BrM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.